—Data Will Be Presented at Upcoming American Association for Cancer Research Meeting--
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced new data will be presented on Locked Nucleic Acid (LNA) based antisense oligonucleotide programs directed against, the androgen receptor (AR), hedgehog pathway GLI2, and beta-catenin. The Company will also present data related to its Customized PEG linker program. These targets and activities are linked to a broad spectrum of cancers.
The abstracts related to these new targets and other Enzon programs are now available at www.aacr.org. These data will be presented at the upcoming 2010 Annual Meeting of the American Association for Cancer Research (AACR) being held April 17-21, 2010 in Washington, DC.
“Silencing of the androgen receptor (AR) with a novel mRNA antisense oligonucleotide causes antitumor effects in xenograft models of prostate cancer.” (Poster # 602)
Poster Presentation from 2 to 5 PM local time on Sunday, April 18, 2010.
“Targeting the hedgehog pathway by LNA oligonucleotide based-GLI2 RNA antagonists, EZN-4482 and EZN-4496, in vitro and in vivo.” (Poster # 600)
Poster Presentation from 2 to 5 PM local time on Sunday, April 18, 2010.
“In vitro and in vivo inhibition of b-catenin by two novel b-catenin RNA antagonists, EZN-3889 and 3892.” (Poster # 601)
Poster Presentation from 2 to 5 PM local time on Sunday, April 18, 2010.
“Customized PEG linkers improve the pharmaceutical properties of cytotoxic small molecules.” (Poster # 2645)
Poster Presentation from 2 to 5 PM local time on Monday, April 19, 2010.
About Enzon
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing important medicines for patients with cancer. Enzon’s drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform and the Locked Nucleic Acid (LNA) technology. Enzon’s receives a royalty revenue stream from licensing partnerships for other products developed using the proprietary PEGylation technology. Further information about Enzon and this press release can be found on the Company’s web site at www.enzon.com.
Forward Looking Statements
There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should,” "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the timing, success and cost of clinical studies; the ability to obtain regulatory approval of products, market acceptance of, and continuing demand for, Enzon’s products and the impact of competitive products and pricing. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the period ended December 31, 2009. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Enzon does not intend to update this information.
CONTACT:
Enzon Pharmaceuticals, Inc.
Craig Tooman, 908-541-8777
EVP, Finance and Chief
Financial Officer
KEYWORDS: United States North America New Jersey
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical
MEDIA:
| Logo |